239 related articles for article (PubMed ID: 26594036)
21. Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice.
Yang L; Niu H; Gao X; Wang Q; Han G; Cao L; Cai C; Weiler J; Yin H
PLoS One; 2013; 8(4):e61584. PubMed ID: 23658612
[TBL] [Abstract][Full Text] [Related]
22. Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.
Verhaart IE; Heemskerk H; Karnaoukh TG; Kolfschoten IG; Vroon A; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
Hum Gene Ther; 2012 Mar; 23(3):262-73. PubMed ID: 22017442
[TBL] [Abstract][Full Text] [Related]
23. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
24. A dystrophic Duchenne mouse model for testing human antisense oligonucleotides.
Veltrop M; van Vliet L; Hulsker M; Claassens J; Brouwers C; Breukel C; van der Kaa J; Linssen MM; den Dunnen JT; Verbeek S; Aartsma-Rus A; van Putten M
PLoS One; 2018; 13(2):e0193289. PubMed ID: 29466448
[TBL] [Abstract][Full Text] [Related]
25. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.
Yin H; Lu Q; Wood M
Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354
[TBL] [Abstract][Full Text] [Related]
26. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
[TBL] [Abstract][Full Text] [Related]
27. Autoimmune response and its long-term consequences after exon-skipping therapy in a Duchenne muscular dystrophy mouse model.
Nordin JZ; Aoki Y
J Pathol; 2019 Nov; 249(3):271-273. PubMed ID: 31322741
[TBL] [Abstract][Full Text] [Related]
28. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy.
Kemaladewi DU; Hoogaars WM; van Heiningen SH; Terlouw S; de Gorter DJ; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; ten Dijke P; 't Hoen PA
BMC Med Genomics; 2011 Apr; 4():36. PubMed ID: 21507246
[TBL] [Abstract][Full Text] [Related]
29. PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.
Negishi Y; Ishii Y; Nirasawa K; Sasaki E; Endo-Takahashi Y; Suzuki R; Maruyama K
Methods Mol Biol; 2018; 1687():185-192. PubMed ID: 29067664
[TBL] [Abstract][Full Text] [Related]
30. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
[TBL] [Abstract][Full Text] [Related]
31. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy.
Jirka SMG; 't Hoen PAC; Diaz Parillas V; Tanganyika-de Winter CL; Verheul RC; Aguilera B; de Visser PC; Aartsma-Rus AM
Mol Ther; 2018 Jan; 26(1):132-147. PubMed ID: 29103911
[TBL] [Abstract][Full Text] [Related]
32. Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice.
Verhaart IE; Tanganyika-de Winter CL; Karnaoukh TG; Kolfschoten IG; de Kimpe SJ; van Deutekom JC; Aartsma-Rus A
Nucleic Acid Ther; 2013 Jun; 23(3):228-37. PubMed ID: 23634945
[TBL] [Abstract][Full Text] [Related]
33. Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies.
Rouillon J; Poupiot J; Zocevic A; Amor F; Léger T; Garcia C; Camadro JM; Wong B; Pinilla R; Cosette J; Coenen-Stass AM; Mcclorey G; Roberts TC; Wood MJ; Servais L; Udd B; Voit T; Richard I; Svinartchouk F
Hum Mol Genet; 2015 Sep; 24(17):4916-32. PubMed ID: 26060189
[TBL] [Abstract][Full Text] [Related]
34. Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.
Sharp PS; Bye-a-Jee H; Wells DJ
Mol Ther; 2011 Jan; 19(1):165-71. PubMed ID: 20924363
[TBL] [Abstract][Full Text] [Related]
35. Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse.
Rayavarapu S; Coley W; Cakir E; Jahnke V; Takeda S; Aoki Y; Grodish-Dressman H; Jaiswal JK; Hoffman EP; Brown KJ; Hathout Y; Nagaraju K
Mol Cell Proteomics; 2013 May; 12(5):1061-73. PubMed ID: 23297347
[TBL] [Abstract][Full Text] [Related]
36. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
37. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.
Walmsley GL; Arechavala-Gomeza V; Fernandez-Fuente M; Burke MM; Nagel N; Holder A; Stanley R; Chandler K; Marks SL; Muntoni F; Shelton GD; Piercy RJ
PLoS One; 2010 Jan; 5(1):e8647. PubMed ID: 20072625
[TBL] [Abstract][Full Text] [Related]
38. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
[TBL] [Abstract][Full Text] [Related]
39. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
[TBL] [Abstract][Full Text] [Related]
40. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
